Page 12 - Landos Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LABP Stock Price | Landos Biopharma Inc Stock Quote (U S : Nasdaq)

LABP | Complete Landos Biopharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Josep bassaganya rieraLandos biopharma incLandos biopharmaAbp analyst estimatesAbp earnings estimatesAbp share estimatesAbp analyst recommendationsAbp ratingsAndos biopharma inc analyst estimatesAndos biopharma inc earnings estimatesAndos biopharma inc analyst recommendationsAndos biopharma inc analyst ratings

Landos Biopharma (LABP) Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis

Landos Biopharma (LABP) Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Fabio cataldiBram verstocktLandos biopharma incLandos biopharmaExecutive vice presidentChief medical officerClinical efficacyActive ulcerative colitis

Landos Biopharma Shares Rise 10% After Positive Trial Data for NX-13

By Chris Wack Landos Biopharma shares were up 10% to $4.31 after the company published positive safety, tolerability, pharmacokinetic and clinical efficacy.

Chris wackLandos biopharmaArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceShare price movement disruptionsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingEquity marketsCommodity financial market newsContent typesFactiva filters

Short Interest in Landos Biopharma, Inc (NASDAQ:LABP) Drops By 10 9%

Landos Biopharma, Inc. (NASDAQ:LABP – Get Free Report) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 14,700 shares, a decrease of 10.9% from the October 15th total of 16,500 shares. Based on an average trading volume of 5,800 shares, the days-to-cover ratio […]

United statesLandos biopharmaVanguard group incRenaissance technologiesBlackrock incGoldman sachs group incAmerica corpLandos biopharma incGet free reportSachs groupVanguard groupNucleotide oligomerization domainLandos biopharma dailyNasdaq labp

Landos Biopharma, Inc (NASDAQ:LABP) Sees Large Decrease in Short Interest

Landos Biopharma, Inc. (NASDAQ:LABP – Get Free Report) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 14,700 shares, a drop of 10.9% from the October 15th total of 16,500 shares. Currently, 0.5% of the shares of the stock are sold short. Based […]

United statesLandos biopharmaGoldman sachs group incLandos biopharma incRenaissance technologiesAmerica corpVanguard group incLandos biopharma company profileGet free reportSachs groupNucleotide oligomerization domainLandos biopharma dailyNasdaq labp